Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Julphar
Cerilliant
Express Scripts
Federal Trade Commission
Colorcon
Merck
Moodys
Healthtrust

Generated: October 22, 2017

DrugPatentWatch Database Preview

Eli Lilly And Co Company Profile

« Back to Dashboard

What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?

ELI LILLY AND CO has six approved drugs.

There are eighteen US patents protecting ELI LILLY AND CO drugs.

There are two hundred and twenty-nine patent family members on ELI LILLY AND CO drugs in forty-three countries and fifty-seven supplementary protection certificates in twelve countries.

Summary for Applicant: Eli Lilly And Co

International Patents:229
US Patents:18
Tradenames:7
Ingredients:6
NDAs:6
Drug Master File Entries: (click here to view)37
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-004Jun 15, 1999DISCNNoNo► Subscribe► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987AB1RXYesNo► Subscribe► Subscribe► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► Subscribe ► Subscribe
Eli Lilly And Co
HUMALOG KWIKPEN
insulin lispro recombinant
SOLUTION;SUBCUTANEOUS205747-001May 26, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-002Jul 10, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► Subscribe ► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-006Dec 23, 1992AB1RXYesNo► Subscribe► Subscribe ► Subscribe
Eli Lilly And Co
VERZENIO
abemaciclib
TABLET;ORAL208716-002Sep 28, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Eli Lilly And Co
HUMALOG KWIKPEN
insulin lispro recombinant
SOLUTION;SUBCUTANEOUS205747-001May 26, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Eli Lilly And Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-006Dec 23, 1992► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-007Jul 6, 2000► Subscribe► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-008Jul 6, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ELI LILLY AND CO drugs

Drugname Dosage Strength Tradename Submissiondate
prasugrel hydrochloride
Tablets5 mg and 10 mg
EFFIENT
7/10/2013
testosterone
Topical Solution30 mg/1.5 mL
AXIRON
1/29/2013

Non-Orange Book Patents for Eli Lilly And Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,427,275Medication dispensing apparatus with triple screw threads for mechanical advantage► Subscribe
6,929,801 Transdermal delivery of antiparkinson agents► Subscribe
5,436,242 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation► Subscribe
8,357,393Transdermal delivery rate control using amorphous pharmaceutical compositions► Subscribe
7,094,422Topical delivery of antifungal agents► Subscribe
7,387,789Transdermal delivery of non-steroidal anti-inflammatory drugs► Subscribe
6,916,486 Transdermal delivery of analgesics► Subscribe
8,177,449Spreading implement► Subscribe
6,916,487 Transdermal delivery of antiemetics► Subscribe
6,964,777 Transdermal delivery of antianxiety agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eli Lilly And Co Drugs

Country Document Number Estimated Expiration
JapanH0641139► Subscribe
European Patent Office1674068► Subscribe
Eurasian Patent Organization015473► Subscribe
New Zealand507980► Subscribe
Japan5114496► Subscribe
Israel103098► Subscribe
South Korea20050045946► Subscribe
Portugal884053► Subscribe
New Zealand578883► Subscribe
Hungary0400644► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eli Lilly And Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2005Austria► SubscribePRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 50:50; REGISTRATION NO/DATE: EU/1/00/142/011 - EU/1/00/142/016 20051005
00397Netherlands► SubscribePRODUCT NAME: PRASUGREL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/08/503/001-014 20090225
973Luxembourg► Subscribe91973, EXPIRES: 20220219
00698Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918
226Luxembourg► SubscribePRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121
13/34Ireland► SubscribePRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
C/GB05/024United Kingdom► SubscribePRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929
91022-0Sweden► SubscribePRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN
C/GB04/036United Kingdom► SubscribePRODUCT NAME: INSULIN DETEMIR, NEB29- TETRADECANOYL- DES(B30) HUMAN INSULIN; NATL REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: CH 56370, 56311, 56372 20031110
2013000062Germany► SubscribePRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND INSULIN ASPART IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/806/001 EU/1/12/806/004-005 EU/1/12/806/007-008 20130121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Cipla
Chubb
Argus Health
Teva
UBS
Cerilliant
US Army
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot